Abstract: An electro-optic modulator includes a doped semiconductor crystal having a crystallographic surface having an amplitude modulation orientation, a first metal electrode located on a first surface of the doped semiconductor crystal, a second metal electrode located on a second surface of the doped semiconductor crystal, and accumulation space charge regions located within surface regions of the doped semiconductor crystal that are proximal to the first metal electrode and the second metal electrode and including excess charge carriers of a same type as majority charge carriers of the doped semiconductor crystal.

Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.

Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.

Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.

Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent ?v?6-mediated diseases such as acute tissue injury, fibrosis, and cancer.

Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent ?v?6-mediated diseases such as fibrosis and cancer.

Abstract: A connected impeller and shaft is provided. The shaft has a first part which provides a threaded portion carrying a thread which screws onto a corresponding threaded portion of the impeller. The shaft also has a second part which provides an abutment surface for engaging a corresponding abutment surface of the impeller when the threaded portions are screwed together, thereby tightening the threads to provide a rotationally fixed connection between the impeller and the shaft. The first part is rotationally fixed relative to the second part at a joint. The threaded portion of the shaft is axially spaced a first distance from the abutment surface of the shaft. The threaded portion of the shaft is axially spaced from the joint by a second distance which is greater than the first distance. The threaded portion of the shaft and the joint are on the same side of the impeller.

Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.

Abstract: The technology disclosed relates to manipulating and visualizing database objects that represent layers and parts of layers in an insurance or other risk transfer program. In particular, a special purpose database system replaces manual use of spreadsheets and supports data visualization. The technology disclosed provides systems and methods for processing and displaying database objects that build a composite coverage structure capable of representing a complex program of multiple insurance policies or other risk transfer instruments during planning and placement. Reporting from the database of progress against the composite coverage structure and updating objects using a visual interface are described.

Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.

Abstract: The present application relates to modified T cell epitopes derived from fungal ribotoxins, including ?-sarcin, clavin, gigantin, mitogillin, and restrictocin, as well as modified ribotoxin molecules comprising one or more of the modified epitopes. The modified ribotoxin molecules inhibit protein synthesis, like the wild type ribotoxins, but exhibit reduced immunogenicity as compared to the corresponding wild type ribotoxin. Another aspect relates to a fusion protein which comprises a modified ribotoxin fused or conjugated or otherwise linked to a targeting molecule that is effective for binding a target of interest. Another aspect relates to the use of the modified ribotoxin or fusion protein for treating or managing a disease or condition.

Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.

Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.

Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.

Abstract: An infuser for alcoholic beverages, having a container of ethyl alcohol and a water source, both of which are hydraulically connected to a volumetric mixing chamber, a water capsule holder located downstream of the volumetric chamber and intended to receive capsules containing single doses of essences, and extracting liquid from the volumetric chamber and injecting same into a capsule. The ethyl alcohol container and the water source are connected to the volumetric chamber by shut-off solenoid valves, and the volumetric chamber contains a main electrode and a plurality of secondary electrodes disposed above the main electrode at different levels.

Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.

Abstract: An input/output module receives application requirements and parameters and a processing module implements production of application code. An architecture code level design phase produces code component architecture artifacts of at least a portion of the application code based on one or more of the application requirements, the parameters, or architecture phase feedback. A high-level design (HLD) phase to produce code HLD artifacts based on one or more of the code component architecture artifacts, the application requirements, the parameters, or HLD phase feedback. A low-level design (LLD) phase to produce code LLD artifacts based on one or more of the code component architecture artifacts, the code HLD artifacts, the application requirements, the parameters, or LLD phase feedback and an application code level development phase to produce code artifacts based on one or more of: the HLD artifacts, the LLD artifacts, the application requirements, the parameters, or code development phase feedback.

Abstract: Disclosed are methods and systems for alerting a user to a change in an audio stream. In an aspect, a user device of the user receives the audio stream, detects a change in an audio pattern occurring in the audio stream, wherein the detection of the change in the audio pattern occurs when the audio stream is muted, and in response to the detection of the change in the audio pattern, provides an alert to the user that indicates the change in the audio pattern has occurred.

Abstract: Wings do not produce lift. It is the thrust provided by an engine (or engines) that enable an aircraft to rise off the ground.